Long-Term Efficacy of Pergolide in Patients with Parkinsonʼs Disease
- 1 April 1986
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 9 (2) , 160-164
- https://doi.org/10.1097/00002826-198604000-00007
Abstract
We report the clinical course of 35 patients with Parkinson's disease who experienced an initially favorable response to pergolide and who were taking the drug for at least 6 months. The duration of pergolide treatment was 6–50 (25 ± 16 SD) months. Of the 14 patients who remained on pergolide for over 2 years, 12 remained less disabled for 26 ± 17 SD months, seven enjoyed increased “on” time for 39 ± 8 SD months, and nine had a lower Hoehn-Yahr stage for 25 ± 17 SD months. Pergolide was discontinued after 5–39 month in eight patients; six patients then deteriorated. Pergolide can remain efficacious in the treatment of Parkinson's disease for up to 50 months.Keywords
This publication has 0 references indexed in Scilit: